TAVR Versus SAVR in Aortic Stenosis: Long Journey, New Roadmap
- PMID: 33663732
- DOI: 10.1016/j.jacc.2021.01.012
TAVR Versus SAVR in Aortic Stenosis: Long Journey, New Roadmap
Keywords: aortic stenosis; surgical aortic valve replacement; transcatheter aortic valve replacement.
Conflict of interest statement
Funding Support And Author Dislosures Prof. Prendergast has received unrestricted research and educational grants from Edwards Lifesciences; and has received speaker/consultancy fees from Abbott, Anteris, and Edwards Lifesciences. Prof. Redwood has served as a proctor for and received speaker fees from Edwards Lifesciences; and has served on the advisory board for Medtronic. Dr. Patterson has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.J Am Coll Cardiol. 2021 Mar 9;77(9):1149-1161. doi: 10.1016/j.jacc.2020.12.052. J Am Coll Cardiol. 2021. PMID: 33663731 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
